Allon Receives Notice of Allowance From European Patent Office for Lead Compound Davunetide (NAP) as Alzheimer's Treatment

Allon Therapeutics Inc. (TSX:NPC) announced today that the European Patent Office has issued a notice of allowance for a patent covering the composition and method of use of the Company's lead neuroprotective compound davenutide (NAP) as a treatment for Alzheimer's disease.

Allon's product candidate davunetide intranasal (AL-108) has demonstrated efficacy in a Phase IIa clinical trial in which short-term and working memory performance was improved in patients with amnestic mild cognitive impairment, a precursor to Alzheimer's disease. The Company will begin additional Phase II trials this year.

Davunetide (NAP) is an eight amino acid peptide, Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln, single letter code NAPVSIPQ (NAP), derived from Allon's activity-dependent neuroprotective protein (ADNP) technology platform.

The European Patent Office allowable claims also include the composition of matter of the nucleic acid sequence that encodes the ADNP protein and the composition of the ADNP protein, as well as davunetide (NAP) derivatives.

About Allon's neuroprotective platforms

Allon's two neuroprotective technology platforms are based on naturally occurring proteins produced by the brain in response to a range of insults. The platforms are activity-dependent neuroprotective protein (ADNP) and activity-dependent neurotrophic factor (ADNF).

Because the two platforms are based on different proteins, the drugs from each are different molecules with different therapeutic mechanisms and distinct commercial opportunities. Clinical-stage drugs davunetide intranasal (AL-108) and davunetide intravenous (AL-208) are derived from ADNP, while preclinical stage drug AL-309 is derived from ADNF. ADNP drugs davunetide intranasal (AL-108) and davunetide intravenous (AL-208) are focused on Alzheimer's disease, frontotemporal dementias, and cognitive impairment. ADNF drug candidate AL-309 is being developed for the treatment of peripheral neuropathies and is administered orally or subcutaneously.

About Allon

Allon Therapeutics Inc. is a clinical-stage biotechnology company developing treatments for major neurodegenerative conditions. Allon's drug davunetide intranasal (AL-108) has demonstrated human efficacy in amnestic mild cognitive impairment, a precursor to Alzheimer's disease. Allon has Phase II human efficacy programs pursuing large underserved markets: Alzheimer's disease, frontotemporal dementia, and schizophrenia-related cognitive impairment. The Company is listed on the Toronto Stock Exchange under the trading symbol "NPC" (Neuro Protection Company(TM)) and based in Vancouver. For additional information please visit the Company's website: www.allontherapeutics.com.

Forward Looking Statements

Statements contained herein, other than those which are strictly statements of historical fact may include forward-looking information. Such statements will typically contain words such as "believes", "may", "plans", "will", "estimate", "continue", "anticipates", "intends", "expects", and similar expressions. While forward-looking statements represent management's outlook based on assumptions that management believes are reasonable, forward-looking statements by their nature are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by them. Such factors include, among others, the inherent uncertainty involved in scientific research and drug development, Allon's early stage of development, lack of product revenues, its additional capital requirements, the risks associated with successful completion of clinical trials and the long lead-times and high costs associated with obtaining regulatory approval to market any product which Allon may eventually develop. Other risk factors include the limited protections afforded by intellectual property rights, rapid technology and product obsolescence in a highly competitive environment and Allon's dependence on collaborative partners and contract research organizations. These factors can be reviewed in Allon's public filings at www.SEDAR.com and should be considered carefully. Readers are cautioned not to place undue reliance on such forward-looking statements and Allon disclaims any obligation to update or announce changes in any such factors except in its periodic filings.

SOURCE: Allon Therapeutics Inc.

Allon Therapeutics Inc. - Investor and Media Contact Aaron Keay Director, Investor Relations (604) 742-2540 or Cell: (604) 323-6911 This email address is being protected from spambots. You need JavaScript enabled to view it. www.allontherapeutics.com